Quince Therapeutics Files DEF 14A on Executive Compensation
Ticker: QNCX · Form: DEF 14A · Filed: Apr 23, 2025 · CIK: 1662774
| Field | Detail |
|---|---|
| Company | Quince Therapeutics, Inc. (QNCX) |
| Form Type | DEF 14A |
| Filed Date | Apr 23, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-compensation, proxy-statement, sec-filing
Related Tickers: QNX
TL;DR
Quince Therapeutics (QNX) DEF 14A out: executive pay details for 2024, including equity awards for Dirk Thye & Christopher Lowe.
AI Summary
Quince Therapeutics, Inc. filed a DEF 14A on April 23, 2025, detailing executive compensation for the fiscal year ending December 31, 2024. The filing includes information on equity awards granted to key personnel such as Dirk Thye, M.D., and Christopher Lowe. It also references the company's former name, Cortexyme, Inc., which was changed on January 4, 2016.
Why It Matters
This filing provides transparency into how Quince Therapeutics compensates its top executives, which can influence investor perception and decisions regarding the company's leadership and future strategy.
Risk Assessment
Risk Level: low — This is a routine DEF 14A filing disclosing executive compensation, which typically does not introduce new material risks.
Key Numbers
- 2024-12-31 — Fiscal Year End (The period covered by the compensation disclosures.)
- 20250423 — Filing Date (Date the DEF 14A was submitted to the SEC.)
- 20160104 — Name Change Date (Date Quince Therapeutics changed its name from Cortexyme, Inc.)
Key Players & Entities
- Quince Therapeutics, Inc. (company) — Filer of the DEF 14A
- Dirk Thye, M.D. (person) — Executive mentioned in compensation details
- Christopher Lowe (person) — Executive mentioned in compensation details
- Cortexyme, Inc. (company) — Former name of Quince Therapeutics
- 0001662774-25-000025 (dollar_amount) — Accession Number for the filing
FAQ
What is the primary purpose of this DEF 14A filing?
The primary purpose is to disclose information regarding the solicitation of proxies for the company's annual meeting of stockholders, including details on executive compensation.
Who are the key individuals whose compensation is detailed in this filing?
The filing details compensation for individuals such as Dirk Thye, M.D., and Christopher Lowe, among other members and executive officers.
What was Quince Therapeutics, Inc. formerly known as?
Quince Therapeutics, Inc. was formerly known as Cortexyme, Inc., with the name change occurring on January 4, 2016.
What is the fiscal year end for which compensation information is being reported?
The compensation information reported pertains to the fiscal year ending December 31, 2024.
What is the company's Standard Industrial Classification (SIC) code?
The company's SIC code is 2836, categorized under Biological Products (No Diagnostic Substances).
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 23, 2025 by Dirk Thye, M.D. regarding Quince Therapeutics, Inc. (QNCX).